THE Department of Health has published a series of fact sheets about the PBS listing of Australia's first biosimilar medicine, which became effective on 01 Apr.
The Brenzys brand of etanercept is now available on the PBS, and is the first biosimilar to be available through community pharmacy as a self-administered therapy.
Brenzys is substitutable ('a' flagged) with the Enbrel brand of etanercept, with the items used to treat a range of autoimmune inflammatory conditions.
The dosage for Brenzys is the same as for the reference brand Enbrel, 50mg of etanercept per week, with the product supplied in single-use pre-filled syringes and pre-filled pens for administration via subcutaneous injection.
The fact sheets are now online at health.gov.au/biosimilars.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Apr 17
